Florida A&M University researchers have published data showing an experimental class of compounds stopped 90% of pancreatic cancer cell movement in lab dishes. Now they face a harder question: can they make it work in a living body? The compounds, called polyisoprenylated cysteinyl amide inhibitors — PCAIs for short — target a genetic mutation long considered hopeless.
KRAS mutations drive most cases of pancreatic ductal adenocarcinoma, the most common and deadly form of the disease. For decades, drug developers called KRAS undruggable.
The Florida A&M team is trying to prove that label wrong. Their paper appeared in the journal Oncotarget. The lab tests measured cell migration — the process tumors use to spread.
Pancreatic cancer metastasizes early. It is aggressive.
Patients run out of options fast. Current drugs lose power as tumors develop resistance. The researchers wrote that “the limited number of drugs to treat KRAS-driven cancers remains a significant healthcare problem, with the current drugs becoming ineffective due to intrinsic resistance.” They added: “novel therapies are needed to combat the KRAS conundrum.” The PCAIs do not attack a single KRAS mutation.
They disrupt the abnormal protein interactions the mutant gene uses to signal cells to grow and move. That matters. Cancer cells evolve.
Block one mutation and they find another route. PCAIs try to jam the whole signaling network.
What comes next
The study stopped at cell cultures. That is a long way from a pharmacy shelf. The next step is animal testing — mice implanted with human pancreatic tumors.
Researchers will watch whether the compounds shrink tumors or block metastasis inside a living system. Those experiments take months.
Results are not yet public. If animal data holds, the process moves to safety trials in humans. That means years.
The U.S. Food and Drug Administration requires Phase I trials to test toxicity in healthy volunteers. Phase II trials test effectiveness in small patient groups.
Phase III trials require hundreds of patients across multiple hospitals. The entire pipeline typically runs a decade or more. Funding is another open question.
Lab work costs less than clinical trials. Universities rely on grants from the National Institutes of Health, private foundations, and cancer research organizations. Florida A&M has not announced a specific timeline or funding source for the next phase.
The team is based at the College of Pharmacy and Pharmaceutical Sciences in Tallahassee. They are not the only group chasing KRAS.
Pharmaceutical companies have poured billions into the target. The first KRAS inhibitor, sotorasib, won FDA approval in 2021 for lung cancer. It targets a specific mutation, G12C.
Pancreatic cancer involves different KRAS variants, including G12D and G12V. PCAIs aim to work across multiple mutations.
That breadth could be an advantage. It also means the compounds must prove they hit cancer cells without harming healthy ones. The lab data does not answer that yet.
The researchers called the current treatment landscape a “KRAS conundrum.” Their paper is a step. The next steps are harder. Animal trials.
Safety data. Clinical recruitment.
Regulatory review. Each stage kills most drug candidates. The 90% migration halt in a dish is real.
Whether it survives translation to patients is not.
